 Ganna Bilousova
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Induced Pluripotent Stem Cells | 17 | 2027 | 277 | 4.970 |
Why?
| | Fibroblasts | 8 | 2027 | 1039 | 2.040 |
Why?
| | Keratinocytes | 6 | 2024 | 249 | 1.730 |
Why?
| | Cell Differentiation | 18 | 2025 | 2054 | 1.350 |
Why?
| | Cellular Reprogramming Techniques | 2 | 2020 | 10 | 1.150 |
Why?
| | Epidermolysis Bullosa Dystrophica | 3 | 2024 | 42 | 0.940 |
Why?
| | CRISPR-Cas Systems | 4 | 2024 | 166 | 0.900 |
Why?
| | Cell Culture Techniques | 4 | 2020 | 375 | 0.900 |
Why?
| | Skin | 3 | 2027 | 759 | 0.820 |
Why?
| | Cellular Senescence | 1 | 2027 | 229 | 0.820 |
Why?
| | Cellular Reprogramming | 3 | 2020 | 98 | 0.780 |
Why?
| | Primary Cell Culture | 2 | 2020 | 173 | 0.730 |
Why?
| | Genetic Engineering | 2 | 2020 | 89 | 0.720 |
Why?
| | Cells, Cultured | 12 | 2027 | 4169 | 0.710 |
Why?
| | Skin Transplantation | 2 | 2024 | 85 | 0.640 |
Why?
| | Skin Aging | 1 | 2019 | 22 | 0.580 |
Why?
| | Genes, Reporter | 1 | 2020 | 278 | 0.580 |
Why?
| | Green Fluorescent Proteins | 1 | 2020 | 407 | 0.540 |
Why?
| | Gene Expression | 2 | 2020 | 1481 | 0.530 |
Why?
| | RNA | 2 | 2020 | 916 | 0.470 |
Why?
| | Pluripotent Stem Cells | 2 | 2014 | 81 | 0.400 |
Why?
| | Gene Editing | 3 | 2024 | 90 | 0.380 |
Why?
| | Collagen Type VII | 2 | 2024 | 27 | 0.380 |
Why?
| | Skin Diseases | 1 | 2014 | 152 | 0.370 |
Why?
| | MicroRNAs | 1 | 2018 | 694 | 0.360 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 29 | 0.330 |
Why?
| | Multipotent Stem Cells | 1 | 2010 | 21 | 0.330 |
Why?
| | RNA, Messenger | 1 | 2018 | 2812 | 0.320 |
Why?
| | Hydrogels | 3 | 2025 | 706 | 0.310 |
Why?
| | Osteoblasts | 1 | 2011 | 146 | 0.310 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2015 | 340 | 0.290 |
Why?
| | Osteogenesis | 1 | 2011 | 205 | 0.290 |
Why?
| | Cell Lineage | 1 | 2010 | 381 | 0.280 |
Why?
| | Embryoid Bodies | 2 | 2022 | 8 | 0.270 |
Why?
| | Aging | 1 | 2019 | 1992 | 0.270 |
Why?
| | Tretinoin | 3 | 2014 | 125 | 0.260 |
Why?
| | Immunoassay | 1 | 2027 | 109 | 0.230 |
Why?
| | Genetic Therapy | 2 | 2019 | 317 | 0.220 |
Why?
| | Amniotic Fluid | 1 | 2025 | 79 | 0.210 |
Why?
| | Humans | 24 | 2027 | 147293 | 0.210 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 79 | 0.200 |
Why?
| | Cell Line | 4 | 2022 | 2832 | 0.200 |
Why?
| | DNA Replication | 1 | 2005 | 250 | 0.200 |
Why?
| | Bone Morphogenetic Protein 4 | 2 | 2014 | 44 | 0.190 |
Why?
| | Leukemia | 1 | 2005 | 247 | 0.190 |
Why?
| | Mice | 9 | 2025 | 18491 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 536 | 0.180 |
Why?
| | Thy-1 Antigens | 1 | 2022 | 11 | 0.180 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 435 | 0.180 |
Why?
| | DNA | 2 | 2024 | 1444 | 0.180 |
Why?
| | GABA Plasma Membrane Transport Proteins | 1 | 2021 | 7 | 0.170 |
Why?
| | Jews | 1 | 2021 | 20 | 0.170 |
Why?
| | Retinal Drusen | 1 | 2021 | 31 | 0.170 |
Why?
| | Retinal Pigment Epithelium | 1 | 2021 | 80 | 0.170 |
Why?
| | Mice, Inbred ICR | 2 | 2011 | 113 | 0.160 |
Why?
| | Biocompatible Materials | 1 | 2025 | 432 | 0.160 |
Why?
| | Cell Polarity | 1 | 2021 | 137 | 0.160 |
Why?
| | Gene Knock-In Techniques | 1 | 2020 | 61 | 0.150 |
Why?
| | Gene Targeting | 1 | 2020 | 81 | 0.150 |
Why?
| | Transcription Activator-Like Effector Nucleases | 1 | 2019 | 6 | 0.150 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 82 | 0.150 |
Why?
| | Bone Morphogenetic Protein 2 | 1 | 2019 | 77 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 230 | 0.150 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2019 | 36 | 0.150 |
Why?
| | Macular Degeneration | 1 | 2021 | 196 | 0.150 |
Why?
| | Animals | 11 | 2025 | 38410 | 0.140 |
Why?
| | Mice, Nude | 2 | 2011 | 680 | 0.140 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 80 | 0.140 |
Why?
| | Chondrogenesis | 1 | 2019 | 88 | 0.140 |
Why?
| | Integrins | 1 | 2019 | 90 | 0.140 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 175 | 0.140 |
Why?
| | Biomimetic Materials | 1 | 2019 | 78 | 0.140 |
Why?
| | Munc18 Proteins | 1 | 2018 | 26 | 0.140 |
Why?
| | Genetic Vectors | 1 | 2020 | 335 | 0.140 |
Why?
| | Immunocompromised Host | 1 | 2020 | 202 | 0.140 |
Why?
| | Exocytosis | 1 | 2018 | 85 | 0.140 |
Why?
| | Models, Animal | 1 | 2020 | 394 | 0.130 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 616 | 0.130 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 236 | 0.130 |
Why?
| | Stem Cells | 2 | 2019 | 630 | 0.130 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 49 | 0.130 |
Why?
| | Regenerative Medicine | 2 | 2022 | 49 | 0.130 |
Why?
| | Transforming Growth Factor beta | 1 | 2019 | 475 | 0.120 |
Why?
| | Epilepsy | 1 | 2021 | 399 | 0.120 |
Why?
| | Transfection | 1 | 2018 | 930 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2017 | 195 | 0.120 |
Why?
| | Folic Acid | 1 | 2017 | 198 | 0.120 |
Why?
| | Peptides | 2 | 2019 | 1003 | 0.120 |
Why?
| | Proteins | 1 | 2021 | 1024 | 0.110 |
Why?
| | Skin Diseases, Genetic | 1 | 2014 | 13 | 0.110 |
Why?
| | Homeostasis | 1 | 2019 | 651 | 0.110 |
Why?
| | Neurons | 2 | 2021 | 1672 | 0.110 |
Why?
| | Embryonic Stem Cells | 1 | 2015 | 124 | 0.110 |
Why?
| | Embryonic Development | 1 | 2015 | 125 | 0.110 |
Why?
| | Signal Transduction | 4 | 2021 | 5272 | 0.100 |
Why?
| | Synapses | 1 | 2018 | 448 | 0.100 |
Why?
| | Mosaicism | 1 | 2014 | 73 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2015 | 201 | 0.100 |
Why?
| | Collagen Type IV | 1 | 2014 | 27 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 586 | 0.100 |
Why?
| | Collagen Type I | 1 | 2014 | 145 | 0.090 |
Why?
| | Cell Adhesion | 1 | 2014 | 451 | 0.090 |
Why?
| | Wnt Signaling Pathway | 1 | 2014 | 212 | 0.090 |
Why?
| | Repressor Proteins | 1 | 2015 | 429 | 0.090 |
Why?
| | Lung | 1 | 2025 | 4141 | 0.080 |
Why?
| | Integrin-Binding Sialoprotein | 1 | 2011 | 6 | 0.080 |
Why?
| | Hypertension, Pulmonary | 2 | 2014 | 1977 | 0.080 |
Why?
| | Sebaceous Glands | 1 | 2010 | 5 | 0.080 |
Why?
| | Keratolytic Agents | 1 | 2010 | 5 | 0.080 |
Why?
| | Osteocalcin | 1 | 2011 | 38 | 0.080 |
Why?
| | Liver | 1 | 2020 | 1916 | 0.080 |
Why?
| | Dermis | 1 | 2010 | 33 | 0.080 |
Why?
| | Hair Follicle | 1 | 2010 | 49 | 0.080 |
Why?
| | Neoplasm Transplantation | 1 | 2010 | 246 | 0.080 |
Why?
| | Epidermis | 1 | 2010 | 156 | 0.080 |
Why?
| | Teratoma | 1 | 2010 | 124 | 0.070 |
Why?
| | Tissue Scaffolds | 1 | 2011 | 221 | 0.070 |
Why?
| | Protein Transport | 2 | 2021 | 442 | 0.070 |
Why?
| | Phenotype | 2 | 2021 | 3216 | 0.070 |
Why?
| | Polyethylene Glycols | 2 | 2025 | 649 | 0.060 |
Why?
| | Neoplasms | 1 | 2023 | 2946 | 0.060 |
Why?
| | E2F2 Transcription Factor | 1 | 2005 | 14 | 0.060 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 915 | 0.060 |
Why?
| | Hydroxyurea | 1 | 2005 | 35 | 0.060 |
Why?
| | Amniocentesis | 1 | 2025 | 20 | 0.060 |
Why?
| | S Phase | 1 | 2005 | 78 | 0.060 |
Why?
| | E2F1 Transcription Factor | 1 | 2005 | 68 | 0.060 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2005 | 68 | 0.060 |
Why?
| | Calcium | 1 | 2010 | 1197 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2015 | 3153 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 307 | 0.050 |
Why?
| | Familial Primary Pulmonary Hypertension | 2 | 2014 | 196 | 0.040 |
Why?
| | Endothelial Cells | 2 | 2022 | 886 | 0.040 |
Why?
| | Gene Silencing | 1 | 2023 | 203 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2024 | 780 | 0.040 |
Why?
| | Chile | 1 | 2021 | 27 | 0.040 |
Why?
| | Colombia | 1 | 2021 | 42 | 0.040 |
Why?
| | Genes, Recessive | 1 | 2021 | 79 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2886 | 0.040 |
Why?
| | Mexico | 1 | 2021 | 233 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2023 | 372 | 0.040 |
Why?
| | Tissue Engineering | 1 | 2025 | 439 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2025 | 547 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 299 | 0.040 |
Why?
| | Smad Proteins | 1 | 2019 | 42 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2021 | 195 | 0.040 |
Why?
| | Organoids | 1 | 2021 | 146 | 0.040 |
Why?
| | Nicotine | 1 | 2021 | 336 | 0.040 |
Why?
| | Syntaxin 1 | 1 | 2018 | 14 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 616 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2019 | 156 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2018 | 219 | 0.030 |
Why?
| | Cartilage | 1 | 2019 | 198 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2019 | 409 | 0.030 |
Why?
| | Metabolism | 1 | 2017 | 44 | 0.030 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2017 | 41 | 0.030 |
Why?
| | Nucleotides | 1 | 2017 | 129 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2625 | 0.030 |
Why?
| | Synaptic Transmission | 1 | 2018 | 293 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2019 | 873 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1504 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 2015 | 86 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2021 | 1368 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1747 | 0.030 |
Why?
| | Female | 4 | 2025 | 80076 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2025 | 6543 | 0.020 |
Why?
| | Mutation | 1 | 2024 | 4130 | 0.020 |
Why?
| | Protein Binding | 1 | 2018 | 2249 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7274 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2529 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2014 | 324 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2197 | 0.020 |
Why?
| | Adult | 2 | 2025 | 41405 | 0.020 |
Why?
| | Male | 2 | 2024 | 73950 | 0.010 |
Why?
| | United States | 1 | 2021 | 16313 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 36821 | 0.010 |
Why?
|
|
Bilousova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|